MNG874
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.341
- PANCREAS_BETA_CELLS+0.305
- INFLAMMATORY_RESPONSE+0.302
- SPERMATOGENESIS+0.275
- ALLOGRAFT_REJECTION+0.271
- TNFA_SIGNALING_VIA_NFKB+0.262
- KRAS_SIGNALING_UP+0.257
- ANGIOGENESIS+0.189
- ESTROGEN_RESPONSE_LATE+0.161
- COAGULATION+0.146
Top 10 suppressed
- MYC_TARGETS_V1-0.544
- DNA_REPAIR-0.536
- PROTEIN_SECRETION-0.520
- UNFOLDED_PROTEIN_RESPONSE-0.472
- MYC_TARGETS_V2-0.423
- OXIDATIVE_PHOSPHORYLATION-0.423
- WNT_BETA_CATENIN_SIGNALING-0.392
- MITOTIC_SPINDLE-0.347
- TGF_BETA_SIGNALING-0.345
- UV_RESPONSE_DN-0.323
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1486496 | GTEX | — | 0.956 |
| 2 | SJEPD001523_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.929 |
| 3 | MDT-AP-1142 | Med | Medulloblastoma | 0.918 |
| 4 | SRR1500617 | GTEX | — | 0.915 |
| 5 | SRR1418604 | GTEX | — | 0.915 |
| 6 | MNG466 | — | — | 0.915 |
| 7 | SRR1336887 | GTEX | — | 0.912 |
| 8 | SRR1370473 | GTEX | — | 0.912 |
| 9 | SRR1459423 | GTEX | — | 0.912 |
| 10 | SRR1395951 | GTEX | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.341 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.305 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.302 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.275 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.271 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.262 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.257 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.189 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.161 | Idelalisib | — uncovered |
| COAGULATION | 0.146 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.146 | Inavolisib | — uncovered |
| HYPOXIA | 0.066 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.058 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.035 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.029 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.009 | Inavolisib | — uncovered |